179 related articles for article (PubMed ID: 17956352)
1. Novel agents for cancer prevention based on nitric oxide.
Rigas B
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1364-8. PubMed ID: 17956352
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets of nitric-oxide-donating aspirin in cancer.
Kashfi K; Rigas B
Biochem Soc Trans; 2005 Aug; 33(Pt 4):701-4. PubMed ID: 16042578
[TBL] [Abstract][Full Text] [Related]
3. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia.
Rigas B
Curr Opin Gastroenterol; 2007 Jan; 23(1):55-9. PubMed ID: 17133086
[TBL] [Abstract][Full Text] [Related]
4. Nitric-oxide-donating NSAIDs as agents for cancer prevention.
Rigas B; Kashfi K
Trends Mol Med; 2004 Jul; 10(7):324-30. PubMed ID: 15242680
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
Williams JL; Borgo S; Hasan I; Castillo E; Traganos F; Rigas B
Cancer Res; 2001 Apr; 61(8):3285-9. PubMed ID: 11309281
[TBL] [Abstract][Full Text] [Related]
6. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
Yeh RK; Chen J; Williams JL; Baluch M; Hundley TR; Rosenbaum RE; Kalala S; Traganos F; Benardini F; del Soldato P; Kashfi K; Rigas B
Biochem Pharmacol; 2004 Jun; 67(12):2197-205. PubMed ID: 15163551
[TBL] [Abstract][Full Text] [Related]
7. Development of novel agents based on nitric oxide for the control of colon cancer.
Kozoni V; Rosenberg T; Rigas B
Acta Pharmacol Sin; 2007 Sep; 28(9):1429-33. PubMed ID: 17723176
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Williams JL; Nath N; Chen J; Hundley TR; Gao J; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2003 Nov; 63(22):7613-8. PubMed ID: 14633677
[TBL] [Abstract][Full Text] [Related]
9. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model.
Ouyang N; Williams JL; Tsioulias GJ; Gao J; Iatropoulos MJ; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2006 Apr; 66(8):4503-11. PubMed ID: 16618778
[TBL] [Abstract][Full Text] [Related]
11. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.
Chattopadhyay M; Goswami S; Rodes DB; Kodela R; Velazquez CA; Boring D; Crowell JA; Kashfi K
Cancer Lett; 2010 Dec; 298(2):204-11. PubMed ID: 20674154
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of nitric oxide-donating aspirin.
Kashfi K; Rigas B
Biochem Biophys Res Commun; 2007 Jul; 358(4):1096-101. PubMed ID: 17512900
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines.
Rosetti M; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Amadori D; Bolla M; Zoli W
Apoptosis; 2006 Aug; 11(8):1321-30. PubMed ID: 16699954
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention.
Hagos GK; Abdul-Hay SO; Sohn J; Edirisinghe PD; Chandrasena RE; Wang Z; Li Q; Thatcher GR
Mol Pharmacol; 2008 Nov; 74(5):1381-91. PubMed ID: 18676677
[TBL] [Abstract][Full Text] [Related]
15. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models.
Kwon KH; Barve A; Yu S; Huang MT; Kong AN
Acta Pharmacol Sin; 2007 Sep; 28(9):1409-21. PubMed ID: 17723174
[TBL] [Abstract][Full Text] [Related]
16. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
Kashfi K; Borgo S; Williams JL; Chen J; Gao J; Glekas A; Benedini F; Del Soldato P; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):978-88. PubMed ID: 15528453
[TBL] [Abstract][Full Text] [Related]
17. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
Spiegel A; Hundley TR; Chen J; Gao J; Ouyang N; Liu X; Go MF; Tsioulias GJ; Kashfi K; Rigas B
Biochem Pharmacol; 2005 Oct; 70(7):993-1000. PubMed ID: 16105666
[TBL] [Abstract][Full Text] [Related]
18. Position in cell cycle controls the sensitivity of colon cancer cells to nitric oxide-dependent programmed cell death.
Jarry A; Charrier L; Bou-Hanna C; Devilder MC; Crussaire V; Denis MG; Vallette G; Laboisse CL
Cancer Res; 2004 Jun; 64(12):4227-34. PubMed ID: 15205335
[TBL] [Abstract][Full Text] [Related]
19. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Chattopadhyay M; Kodela R; Nath N; Dastagirzada YM; Velázquez-Martínez CA; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):715-22. PubMed ID: 22222427
[TBL] [Abstract][Full Text] [Related]
20. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
